New shot after heart attack slashes 'Bad' cholesterol, study hopes
NCT ID NCT04951856
First seen Jan 09, 2026 · Last updated Jun 16, 2026 · Updated 24 times
Summary
This study tests if adding evolocumab (a powerful cholesterol-lowering injection) to standard care helps heart attack patients reach very low LDL cholesterol goals and reduces the risk of death or unplanned hospital visits. About 2,166 adults who had a recent heart attack and needed a stent procedure will be randomly assigned to get evolocumab or usual treatment. The goal is to see if the extra drug leads to better outcomes over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSTEMI - NON-ST SEGMENT ELEVATION MI are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ACTION Group, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière (APHP), UPMC
Paris, 75013, France
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.